Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome

Journal of the Neurological Sciences

Volumn 294, Issue 1-2, 2010, Pages 107-111

  Shehadah, Amjad ^a   Chen, Jieli ^a   Cui, Xu ^a   Roberts, Cynthia ^a   Lu, Mei ^b   Chopp, Michael ^a,c  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

^c OAKLAND UNIVERSITY   (United States)

Author keywords

Axonal damage; Microglia; Niaspan; Nogo receptor; Simvastatin; Stroke

Indexed keywords

AMYLOID PRECURSOR PROTEIN; NICOTINIC ACID; NOGO 66 RECEPTOR; SIMVASTATIN; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; CALCIUM BINDING PROTEIN; CELL SURFACE RECEPTOR; DELAYED RELEASE FORMULATION; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MYELIN PROTEIN; NEUROPROTECTIVE AGENT; RECEPTOR; RTN4R PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL STROKE; FUNCTION TEST; IMMUNOREACTIVITY; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOTHERAPY; NERVE FIBER DEGENERATION; NEUROLOGIC EXAMINATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STROKE; TREATMENT DURATION; TREATMENT INDICATION; ANIMAL; BRAIN; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; NERVE FIBER; PATHOLOGY; RANDOMIZATION; TREATMENT OUTCOME; WISTAR RAT;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AXONS; BRAIN; BRAIN ISCHEMIA; CALCIUM-BINDING PROTEINS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICROGLIA; NEUROPROTECTIVE AGENTS; NIACIN; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, PEPTIDE; SIMVASTATIN; STROKE; TREATMENT OUTCOME; GPI-LINKED PROTEINS; MICROFILAMENT PROTEINS; MYELIN PROTEINS; RECEPTORS, CELL SURFACE;

EID: 77953292135     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.03.020     Document Type: Article

References (55)

1. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284 10 (2000) 1263-1270
2. Carlson L.A. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 58 7 (2004) 706-713
3. Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 101 8A (2008) 3B-8B
4. Vo A.N., and Kashyap M.L. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert Rev Cardiovasc Ther 6 10 (2008) 1303-1310
5. Ward S., Lloyd Jones M., Pandor A., Holmes M., Ara R., Ryan A., et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11 14 (2007) 1-160 iii-iv
6. Aviram M., Rosenblat M., Bisgaier C.L., and Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 2 (1998) 271-280
7. Diomede L., Albani D., Sottocorno M., Donati M.B., Bianchi M., Fruscella P., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21 8 (2001) 1327-1332
8. Pandian A., Arora A., Sperling L.S., and Khan B.V. Targeting multiple dyslipidemias with fixed combinations-focus on extended release niacin and simvastatin. Vasc Health Risk Manag 4 5 (2008) 1001-1009
9. Ballantyne C.M., Davidson M.H., McKenney J., Keller L.H., Bajorunas D.R., and Karas R.H. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 101 10 (2008) 1428-1436
10. Karas R.H., Kashyap M.L., Knopp R.H., Keller L.H., Bajorunas D.R., and Davidson M.H. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 8 2 (2008) 69-81
11. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 23 (2004) 3512-3517
12. Chen J., Zhang Z.G., Li Y., Wang Y., Wang L., Jiang H., et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53 6 (2003) 743-751
13. Chen J., Zhang C., Jiang H., Li Y., Zhang L., Robin A., et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 25 2 (2005) 281-290
14. Chen J., Cui X., Zacharek A., Ding G.L., Shehadah A., Jiang Q., et al. Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke. J Cereb Blood Flow Metab 29 5 (2009) 911-920
15. Chen J., Cui X., Zacharek A., Jiang H., Roberts C., Zhang C., et al. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 62 1 (2007) 49-58
16. Di Giovanni S. Molecular targets for axon regeneration: focus on the intrinsic pathways. Expert Opin Ther Targets 13 12 (2009) 1387-1398
17. Benowitz L.I., and Yin Y. Combinatorial treatments for promoting axon regeneration in the CNS: strategies for overcoming inhibitory signals and activating neurons' intrinsic growth state. Dev Neurobiol 67 9 (2007) 1148-1165
18. Park E., Velumian A.A., and Fehlings M.G. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma 21 6 (2004) 754-774
19. Wang F., Liang Z., Hou Q., Xing S., Ling L., He M., et al. Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. Neurosci Lett 417 3 (2007) 255-260
20. Bramlett H.M., and Dietrich W.D. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab 24 2 (2004) 133-150
21. Schilling M., Besselmann M., Leonhard C., Mueller M., Ringelstein E.B., and Kiefer R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 183 1 (2003) 25-33
22. Kaushal V., and Schlichter L.C. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 28 9 (2008) 2221-2230
23. Block F., Peters M., and Nolden-Koch M. Expression of IL-6 in the ischemic penumbra. Neuroreport 11 5 (2000) 963-967
24. Wang Q., Tang X.N., and Yenari M.A. The inflammatory response in stroke. J Neuroimmunol 184 1-2 (2007) 53-68
25. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 100 14 (2003) 8514-8519
26. Zhang Z., Chopp M., and Powers C. Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. Brain Res 744 2 (1997) 189-198
27. Chen J., Zacharek A., Li A., Zhang C., Ding J., Roberts C., et al. Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. Neuroscience 141 2 (2006) 737-744
28. Chen J., Li Y., Wang L., Zhang Z., Lu D., Lu M., et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 32 4 (2001) 1005-1011
29. Chen J., Sanberg P.R., Li Y., Wang L., Lu M., Willing A.E., et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 32 11 (2001) 2682-2688
30. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., and Sharp F.R. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10 2 (1990) 290-293
31. Li Y., Jiang N., Powers C., and Chopp M. Neuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1 immunoreactivity after focal cerebral ischemia in rats. Stroke 29 9 (1998) 1972-1980 discussion 1980-1971
32. Chen J., Zhang Z.G., Li Y., Wang L., Xu Y.X., Gautam S.C., et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 92 6 (2003) 692-699
33. Calza L., Giardino L., Giuliani A., Aloe L., and Levi-Montalcini R. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Natl Acad Sci U S A 98 7 (2001) 4160-4165
34. Lu M., Chen J., Lu D., Yi L., Mahmood A., and Chopp M. Global test statistics for treatment effect of stroke and traumatic brain injury in rats with administration of bone marrow stromal cells. J Neurosci Methods 128 1-2 (2003) 183-190
35. Sherriff F.E., Bridges L.R., and Sivaloganathan S. Early detection of axonal injury after human head trauma using immunocytochemistry for beta-amyloid precursor protein. Acta Neuropathol 87 1 (1994) 55-62
36. Leclercq P.D., McKenzie J.E., Graham D.I., and Gentleman S.M. Axonal injury is accentuated in the caudal corpus callosum of head-injured patients. J Neurotrauma 18 1 (2001) 1-9
37. Karnezis T., Mandemakers W., McQualter J.L., Zheng B., Ho P.P., Jordan K.A., et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 7 7 (2004) 736-744
38. Pluchino S., Quattrini A., Brambilla E., Gritti A., Salani G., Dina G., et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422 6933 (2003) 688-694
39. Li S., Kim J.E., Budel S., Hampton T.G., and Strittmatter S.M. Transgenic inhibition of Nogo-66 receptor function allows axonal sprouting and improved locomotion after spinal injury. Mol Cell Neurosci 29 1 (2005) 26-39
40. Ito D., Imai Y., Ohsawa K., Nakajima K., Fukuuchi Y., and Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57 1 (1998) 1-9
41. Imai H., McCulloch J., Graham D.I., Masayasu H., and Macrae I.M. New method for the quantitative assessment of axonal damage in focal cerebral ischemia. J Cereb Blood Flow Metab 22 9 (2002) 1080-1089
42. Kalaria R.N., Bhatti S.U., Palatinsky E.A., Pennington D.H., Shelton E.R., Chan H.W., et al. Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport 4 2 (1993) 211-214
43. Kawarabayashi T., Shoji M., Harigaya Y., Yamaguchi H., and Hirai S. Expression of APP in the early stage of brain damage. Brain Res 563 1-2 (1991) 334-338
44. Blumbergs P.C., Scott G., Manavis J., Wainwright H., Simpson D.A., and McLean A.J. Staining of amyloid precursor protein to study axonal damage in mild head injury. Lancet 344 8929 (1994) 1055-1056
45. McKenzie K.J., McLellan D.R., Gentleman S.M., Maxwell W.L., Gennarelli T.A., and Graham D.I. Is beta-APP a marker of axonal damage in short-surviving head injury?. Acta Neuropathol 92 6 (1996) 608-613
46. Hunt D., Coffin R.S., and Anderson P.N. The Nogo receptor, its ligands and axonal regeneration in the spinal cord; a review. J Neurocytol 31 2 (2002) 93-120
47. Domeniconi M., Cao Z., Spencer T., Sivasankaran R., Wang K., Nikulina E., et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 35 2 (2002) 283-290
48. Wang K.C., Koprivica V., Kim J.A., Sivasankaran R., Guo Y., Neve R.L., et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 417 6892 (2002) 941-944
49. McKerracher L., and Winton M.J. Nogo on the go. Neuron 36 3 (2002) 345-348
50. Harvey P.A., Lee D.H., Qian F., Weinreb P.H., and Frank E. Blockade of Nogo receptor ligands promotes functional regeneration of sensory axons after dorsal root crush. J Neurosci 29 19 (2009) 6285-6295
51. Lee J.K., Kim J.E., Sivula M., and Strittmatter S.M. Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci 24 27 (2004) 6209-6217
52. Rogove A.D., Siao C., Keyt B., Strickland S., and Tsirka S.E. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 112 Pt 22 (1999) 4007-4016
53. Zhang N., Komine-Kobayashi M., Tanaka R., Liu M., Mizuno Y., and Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 36 10 (2005) 2220-2225
54. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., and Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95 26 (1998) 15769-15774
55. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96 23 (1999) 13496-13500